Zai Lab Announces Upcoming Presentations in February Investor Conferences

SHANGHAI and SAN FRANCISCO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited ZLAB HKEX: 9688))), an innovative commercial-stage biopharmaceutical company, today announced that senior management from Zai Lab will be presenting in the following upcoming virtual investor conferences in February. Details are as follows:

Guggenheim Healthcare Talks 2021 Oncology Day
Fireside chat: Thursday, February 11, 2021 at 12:00 p.m. ET

2021 SVB Leerink Global Healthcare Conference
Presentation: Friday, February 26, 2021 at 8:00 a.m. ET

A live webcast of the 2021 SVB Leerink Global Healthcare Conference presentation will be available under "Events & Presentations" in the "Investor Relations" section of Zai Lab's website. An archived replay will be available for 90 days following the event.

About Zai Lab

Zai Lab ZLAB HKEX: 9688))) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and drug candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab
Billy Cho, CFO
+86 137 6151 2501
billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
rimai@burnsmc.com / rflamm@burnsmc.com

Investors: Pete Rahmer / Mike Zanoni
Endurance Advisors, on behalf of Zai Lab
415-515-9763 / 610-442-8570
prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com

Zai Lab Limited

Source: Zai Lab Limited